Gut microbiota causally affects drug-induced liver injury via plasma metabolites: a Mendelian randomization study
Haoshuang Fu,Shuang Zhao,Shuying Song,Qing Xie
DOI: https://doi.org/10.3389/fmicb.2024.1432049
IF: 5.2
2024-07-18
Frontiers in Microbiology
Abstract:Background: The gut microbiota and plasma metabolites play important roles in the progression of drug-induced liver injury (DILI). We investigated the causal associations between the gut microbiota, plasma metabolome, and DILI. Methods: The summary data for gut microbiota ( n = 18,340), plasma metabolome ( n = 8,299), and DILI ( n = 366,838) were obtained from the large genome-wide association studies. A two-sample Mendelian randomization was performed to explore the associations between the gut microbiota, plasma metabolome, and DILI. Additionally, a two-step Mendelian randomization was performed to explore the potential metabolites. Results: Five taxa were causally associated with DILI, including Oscillospira [odds ratio (OR) = 2.257, 95% confidence interval (CI) = 1.110–4.590], Blautia (OR = 2.311, 95% CI = 1.010–5.288), Roseburia (OR = 2.869, 95% CI = 1.429–5.761), Fusicatenibacter (OR = 1.995, 95% CI = 1.024–3.890), and Prevotella 7 (OR = 1.549, 95% CI = 1.065–2.253). Moreover, 53 metabolites were causally associated with DILI. After mediation analysis, four taxa were found to affect DILI through five mediation metabolites. N6-carbamoylthreonyladenosine mediated the effect of Blautia on DILI. Acetylcarnitine mediated the effect of Fusicatenibacter on DILI. In addition, 4-cholesten-3-one mediated the effect of Prevotella 7 on DILI. Furthermore, 5,6-dihydrothymine levels and the salicylate-to-citrate ratio mediated the effect of Oscillospira on DILI. Conclusion: We found that the gut microbiota could affect DILI through plasma metabolites, which could serve as potential biomarkers for risk stratification and elucidate underlying mechanisms for further investigation of DILI.
microbiology